The Path to Fair PBM Competition
When control over prescription drug access rests with only a few players, the result is not just market imbalance — it is higher plan costs, increased financial pressures, and ultimately reduced affordability for patients.
Cigna Launches Mental Health Collaboration with Headspace
Cigna Healthcare has partnered with Headspace to offer over 7 million members access to Headspace’s digital mental health tools.
Novel Novartis Malaria Drug Shows Promise to Become New Asset Against Resistant Strains
Phase 3 results for the Novartis malaria drug “GanLum” show it was comparable to the standard of care and led to cure rates that top the threshold recommended by the World Health Organization. If approved, this new combination drug would become the first novel malaria therapy in more than 25 years.
The 340B Program’s New Rebate Pilot Won’t Fix Its Problems
The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with a major lack of transparency about how savings are used to benefit patients. As HRSA launches a new rebate-based model meant to boost oversight, experts warned that it could instead burden smaller providers and fail to address the program’s deeper flaws.
presented by
Turning AI Insights into Meaningful Action: The Future of Healthcare Navigation
The confluence of AI and predictive analytics is rapidly transforming healthcare and benefits management, shifting the focus from reactive automation to proactive anticipation.